This inventor holds 7 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignee: Oncotherapy Science, Incorporated. Active years: 2013-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2013-2019
Title: The Innovative Contributions of Yusuke Tomita in Cancer Immunotherapy
Introduction: Yusuke Tomita is an accomplished inventor based in Kumamoto, Japan, known for his significant contributions to the field of cancer immunotherapy. With a portfolio of seven patents, he has demonstrated a commitment to advancing medical science through innovative peptide-based therapies. His work focuses on the development of epitope peptides that activate Th1 cells, playing a crucial role in enhancing the immune response against cancers.
Latest Patents: Among his latest patents are innovations involving CDCA1 epitope peptides for Th1 cells and KIF20A epitope peptides for Th1 cells. The patent on CDCA1-derived epitope peptides reveals isolated peptides that can be recognized by MHC class II molecules, leading to the induction of Th1 cells and CDCA1-specific cytotoxic T lymphocytes. This innovation holds promise for improving immune responses, particularly in the context of cancer immunotherapy. Similarly, the KIF20A epitope patent outlines peptides that also target Th1 cells, with a similar mechanism of inducing a robust immune response. Both patent disclosures include various components such as polynucleotides, antigen-presenting cells (APCs), and methods of induction, as well as pharmaceutical compositions aimed at cancer treatment and prevention.
Career Highlights: Yusuke Tomita's career is marked by his affiliation with Oncotherapy Science, Incorporated, where he collaborates with a team dedicated to pioneering research in immunotherapy. His patents underscore his role as a leading figure in this innovative field, positioning him as an expert in developing novel therapies that harness the body's immune system to combat cancer.
Collaborations: In his journey, Tomita has worked alongside esteemed colleagues such as Yasuharu Nishimura and Ryuji Osawa. These collaborations have been instrumental in advancing their shared vision of effective cancer therapies through innovative research and development.
Conclusion: Yusuke Tomita's impactful work on epitope peptides represents a significant step toward improving cancer immunotherapy options. His innovative patents showcase the potential of peptide-based treatments in enhancing the immune response against cancer. Through his continued efforts, Tomita is likely to inspire further advancements in medical science and contribute significantly to the field of oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile